Skip to main content
Applied BioCode logo

Applied BioCode — Investor Relations & Filings

Ticker · 6598 ISIN · KYG0488D1051 TW Manufacturing
Open in API
Filings indexed 27 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country TW Taiwan
Listing TW 6598

About Applied BioCode

www.ApBioCode.com/tw

Applied BioCode Corporation is a developer and manufacturer of high-throughput multiplex molecular diagnostic solutions. The company utilizes proprietary digital biological barcode technology to facilitate the simultaneous detection of multiple pathogens from a single clinical sample. Its primary platform, the BioCode MDx-3000, supports a range of syndromic panels, including FDA-cleared assays for gastrointestinal and respiratory infections, as well as specialized tests for SARS-CoV-2, influenza, and sexually transmitted infections. Designed to optimize laboratory workflows, the system offers customizable reporting through data masking and provides cost-effective, large-scale testing capabilities. The company’s portfolio serves clinical laboratories and research institutions by providing comprehensive pathogen detection with high sensitivity and specificity.

Recent filings

Filing Released Lang Actions
115年05月僑外投資持股
Regulatory Filings Classification · 82% confidence The document is a Taiwan MOPS (Market Observation Post System) disclosure titled “僑外及大陸地區投資人投資持股情形統計表,” showing statistics of overseas Chinese, foreign, and Mainland China investors’ shareholdings before and after a shareholder meeting. It is a routine regulatory shareholding status report rather than an annual report, earnings release, management presentation, or voting results. It does not constitute an AGM presentation, financial statements, proxy materials, or a major shareholding threshold change notice. Therefore, it falls under general regulatory filings as a mandated compliance disclosure.
2026-05-22 Chinese
114年第4季財務報告書 — 202504_6598_AIA.pdf
Audit Report / Information Classification · 92% confidence The document is the independent auditor’s report and the consolidated financial statements for the years ended December 31, 2025 and 2024. It contains the auditor’s opinion, key audit matters, audit procedures, and the consolidated balance sheets. It does not include broader management discussion, strategic commentary, or narrative found in an Annual Report, nor is it a simple notice of publication. It is a standalone audited financial statement package, fitting the “Audit Report / Information” category.
2026-05-20 English
114年第4季財務報告書 — 202504_6598_AI1.pdf
Audit Report / Information Classification · 90% confidence The document is titled “合併財務報告暨會計師查核報告” for 2025 and 2024, containing the auditor’s opinion, key audit matters, and full consolidated financial statements with notes and disclosures. It is a standalone audited financial report rather than MD&A or an earnings release. This fits the “Audit Report / Information (AR)” category.
2026-05-20 Chinese
114年第4季財務報告書 — 202503_6598_AI1.pdf
Interim / Quarterly Report Classification · 96% confidence The document is titled “合併財務報告暨會計師核閱報告” for the third quarter of 2025 and 2024, prepared under IFRS 34 “Interim Financial Reporting” and includes consolidated balance sheet, income statement, cash flow, equity changes and detailed notes, along with the auditor’s review report. It clearly constitutes a full interim/quarterly report rather than an announcement or a standalone audit opinion. Therefore the correct classification is an Interim / Quarterly Report (IR). 9M 2025
2026-05-20 Chinese
114年第4季財務報告書 — 202502_6598_AI1.pdf
Interim / Quarterly Report Classification · 90% confidence The document is a consolidated financial report for the six months ended June 30, 2025 and June 30, 2024, prepared under IFRS 34 “Interim Financial Reporting” and includes the auditor’s review report, balance sheet, income statement, statement of changes in equity, cash flow statement and detailed notes. It is not merely an announcement or notice but contains full interim financial statements and auditor’s report for the second quarter period. Therefore, it is classified as an Interim / Quarterly Report. H1 2025
2026-05-20 Chinese
114年第4季財務報告書 — 202501_6598_AI1.pdf
Interim / Quarterly Report Classification · 94% confidence The document is a consolidated financial report and auditor’s review report for the first quarter of 2025 and comparative Q1 2024. It explicitly references International Accounting Standard 34 “Interim Financial Reporting,” provides complete interim financial statements (balance sheet, income statement, cash flows, equity changes, and detailed notes), and includes the auditor’s review opinion. This satisfies the criteria for a comprehensive quarterly (interim) report rather than a short earnings release or an annual report. Therefore, it is classified as an Interim / Quarterly Report (IR). Q1 2025
2026-05-20 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.